Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1A | P54750 | 18/20 | 0.85 |
| ▸ | MEN1 | O00255 | 2/20 | 0.85 |
| ▸ | LMNA | P02545 | 2/20 | 0.85 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.85 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.85 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.85 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.85 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.85 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.85 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.85 |
| ▸ | MAPT | P10636 | 1/20 | 0.85 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.85 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.85 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.85 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.85 |
| ▸ | DRD3 | P35462 | 1/20 | 0.85 |
| ▸ | HTR2B | P41595 | 1/20 | 0.85 |
| ▸ | BLM | P54132 | 1/20 | 0.85 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Apovincamine SCHEMBL29421625 | 1.00 | PDE1A (0.85) | PDE1AMEN1LMNAKMT2AHIF1A | |
| Apovincamine SCHEMBL10574604 | 1.00 | PDE1A (0.85) | PDE1AMEN1LMNAKMT2AHIF1A | |
| Apovincamine SCHEMBL10571224 | 1.00 | PDE1A (0.85) | PDE1AMEN1LMNAKMT2AHIF1A | |
| Apovincamine SCHEMBL11621460 | 0.96 | PDE1A (0.79) | PDE1AMEN1LMNAKMT2AHIF1A | |
| Apovincamine SCHEMBL11619316 | 0.95 | PDE1A (0.77) | PDE1AMEN1LMNAKMT2AHIF1A | |
| Apovincamine SCHEMBL11619228 | 0.92 | PDE1A (0.72) | PDE1AMEN1LMNAKMT2AHIF1A | |
| Apovincamine SCHEMBL11619498 | 0.92 | PDE1A (0.72) | PDE1AMEN1LMNAKMT2AHIF1A | |
| Apovincamine SCHEMBL11619109 | 0.92 | PDE1A (0.72) | PDE1AMEN1LMNAKMT2AHIF1A | |
| Vinpocetine SCHEMBL7947532 | 0.92 | PDE1A (1.00) | PDE1AMEN1LMNAKMT2AHIF1A | |
| Vinpocetine SCHEMBL21098929 | 0.92 | PDE1A (1.00) | PDE1AMEN1LMNAKMT2AHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 410 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119548497-A | Method for treating myopia by using vinpocetine | 温州医科大学附属眼视光医院 | 2025-03-04 | — | — | CN | claimed |
| CN-118344985-A | Genetically engineered bacterium for producing additional value products based on glucose, construction method and application | 浙江大学杭州国际科创中心 | 2024-07-16 | — | — | CN | claimed |
| EP-4364736-A1 | METHOD FOR TREATING MYOPIA WITH VINPOCETINE | The Eye Hospital of Wenzhou Medical University (CN) | 2024-05-08 | — | — | EP | claimed |
| WO-2023001176-A1 | METHOD FOR TREATING MYOPIA WITH VINPOCETINE | 温州医科大学附属眼视光医院 | 2023-01-26 | — | — | WO | claimed |
| CN-115634226-A | Method for treating myopia by vinpocetine | 温州医科大学附属眼视光医院 | 2023-01-24 | — | — | CN | claimed |
| US-20220233705-A1 | COMBINED THERAPIES OF ACTIVATABLE IMMUNE CHECKPOINT INHIBITORS AND CONJUGATED ACTIVATABLE ANTIBODIES | CYTOMX THERAPEUTICS INC (US) | 2022-07-28 | — | — | US | claimed |
| CN-112649522-B | Method for detecting related substances vinblastic acid and apovincamine acid in injection | 海南葫芦娃药业集团股份有限公司 | 2022-02-22 | — | — | CN | claimed |
| EP-3930761-A1 | COMBINED THERAPIES OF ACTIVATABLE IMMUNE CHECKPOINT INHIBITORS AND CONJUGATED ACTIVATABLE ANTIBODIES | CytomX Therapeutics, Inc. (US) | 2022-01-05 | — | — | EP | claimed |
| CN-113677372-A | Combination therapy of activatable immune checkpoint inhibitors and conjugated activatable antibodies | 西托姆克斯治疗公司 | 2021-11-19 | — | — | CN | claimed |
| CN-110950859-B | Preparation method of vinpocetine | 广州一品红制药有限公司 | 2021-04-30 | — | — | CN | claimed |
| EP-0573260-A1 | New alkaloid derivatives, their use and pharmaceutical formulations containing them | INDENA S.p.A. (IT) | 1993-12-08 | — | — | EP | claimed |
| EP-0038619-B1 | PROCESS FOR PREPARING VINCAMINE AND RELATED ALKALOIDS | INVERNI DELLA BEFFA S.P.A. (IT) | 1984-12-05 | — | — | EP | claimed |
| EP-0052238-B1 | A NEW VINCAMINE DERIVATIVE, A METHOD FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | MEDEA RESEARCH S.r.l. (IT) | 1984-05-09 | — | — | EP | claimed |
| EP-0045918-B1 | A PROCESS FOR THE SYNTHESIS OF VINCAMINE AND RELATED INDOLE ALKALOIDS | Mora, Paolo Corvi (IT) | 1983-10-26 | — | — | EP | claimed |
| EP-0021923-B1 | PROCESS FOR THE PREPARATION OF VINCAMINE DERIVATIVES | SYNTHELABO (FR) | 1983-09-07 | — | — | EP | claimed |
| EP-0052238-A1 | A new vincamine derivative, a method for its preparation and pharmaceutical compositions containing it | MEDEA RESEARCH S.r.l. (IT) | 1982-05-26 | — | — | EP | claimed |
| US-4316029-A | Synthesis of vincaminic acid derivatives | SYNTHELABO (FR) | 1982-02-16 | — | — | US | claimed |
| EP-0038619-A2 | Process for preparing vincamine and related alkaloids | INVERNI DELLA BEFFA S.P.A. (IT) | 1981-10-28 | — | — | EP | claimed |
| EP-0021923-A1 | Process for the preparation of vincamine derivatives | SYNTHELABO (FR) | 1981-01-07 | — | — | EP | claimed |
| US-4122179-A | VASODILATORS | Mora, Enrico Corvi (IT) | 1978-10-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220233705-A1 | COMBINED THERAPIES OF ACTIVATABLE IMMUNE CHECKPOINT INHIBITORS AND CONJUGATED ACTIVATABLE ANTIBODIES | CD274, PDCD1LG2, PDCD1 | PDE1A 1988/4885MEN1 1919/4885LMNA 3403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.